Cargando…
Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and...
Autores principales: | Rustin, G. J., Quinnell, T. G., Johnson, J., Clarke, H., Nelstrop, A. E., Bollag, W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074772/ https://www.ncbi.nlm.nih.gov/pubmed/8912548 |
Ejemplares similares
-
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016) -
CA-125 is not a useful marker in metastatic breast cancer.
por: Seckl, M. J., et al.
Publicado: (1992) -
Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
por: Krell, Daniel, et al.
Publicado: (2017) -
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004) -
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001)